Continuous glucose monitoring systems maker DexCom, Inc. and Tandem, the developer of first ever touch-screen insulin pump, announced that they have signed a Development and Commercialization Agreement to integrate a future generation of DexCom’s continuous glucose monitoring (CGM) technology with Tandem’s t:slim(TM) Insulin Delivery System.
The Development and Commercialization Agreement is non-exclusive and limited to the U.S. market. Under the terms of the Agreement, Tandem will pay DexCom a technology license fee of $3 million, reimburse DexCom’s development, clinical and regulatory expenses, and upon commercialization of the combined system, Tandem will pay DexCom a royalty of $100 for each CGM-enabled insulin pump sold.
Tandem’s new t:slim(TM) insulin pump was approved by the FDA in November 2011 and is expected to be available by the second half of 2012.
